SCHEMBL21223948

SCHEMBL21223948

CSc1c[nH]c(=O)cc1-c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.43
PARP1 P09874 1/20 0.42
KDM4E B2RXH2 4/20 0.41
ALDH1A1 P00352 5/20 0.41
KMT2A Q03164 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
HPGD P15428 2/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
PTGS2 P35354 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
PDE3B Q13370 1/20 0.37
PDE3A Q14432 1/20 0.37
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23396897 0.76 KDM4E (0.49) NOTUMPARP1KDM4EALDH1A1SMN1; SMN2
SCHEMBL19815616 0.76 NOTUM (0.47) NOTUMPARP1KDM4EALDH1A1KMT2A
SCHEMBL16475094 0.74 PARP1 (0.48) NOTUMPARP1KDM4EALDH1A1KMT2A
SCHEMBL2333643 0.72 BACE1 (0.52) NOTUMPARP1ALDH1A1SMN1; SMN2HPGD
SCHEMBL21223867 0.72 NOTUM (0.47) NOTUMPARP1KDM4EALDH1A1KMT2A
SCHEMBL21105009 0.71 NOTUM (0.43) NOTUMPARP1KDM4EALDH1A1SMN1; SMN2
SCHEMBL23066572 0.69 ADRA1A (0.45) KDM4EALDH1A1RXFP1SMN1; SMN2MAPK1
SCHEMBL18594367 0.69 ALDH1A1 (0.43) KDM4EALDH1A1KMT2ASMN1; SMN2HPGD
SCHEMBL19817301 0.69 PRKAB2 (0.54) NOTUMPARP1KDM4EALDH1A1
SCHEMBL19815385 0.69 NOTUM (0.44) NOTUMPARP1KDM4EALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11807646-B2 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) ALMAC DISCOVERY LIMITED (GB) 2023-11-07 US disclosed
EP-3746432-B1 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) ALMAC DISCOVERY LTD (GB) 2022-12-14 EP disclosed
US-20220033397-A1 PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) ALMAC DISCOVERY LTD (GB) 2022-02-03 US disclosed
EP-3890829-A1 PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) Almac Discovery Limited (GB) 2021-10-13 EP disclosed
CN-113365696-A Pharmaceutical compounds and their use as inhibitors of ubiquitin-specific protease 19(USP19) 阿尔麦克探索有限公司 2021-09-07 CN disclosed
US-20210070773-A1 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) ALMAC DISCOVERY LIMITED (GB) 2021-03-11 US disclosed
CN-112135818-A 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin-specific protease 19(USP19) 阿尔麦克探索有限公司 2020-12-25 CN disclosed
EP-3746432-A1 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) Almac Discovery Limited (GB) 2020-12-09 EP disclosed
WO-2020115501-A1 PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) ALMAC DISCOVERY LIMITED (GB) 2020-06-11 WO disclosed
WO-2019150119-A1 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) ALMAC DISCOVERY LIMITED (GB) 2019-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220033397-A1 PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) USP19, USP16, USP18 NOTUM 2438/4885PARP1 2288/4885KDM4E 578/4885
US-11807646-B2 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) USP19, USP16, USP18 NOTUM 2764/4885PARP1 2080/4885KDM4E 256/4885
US-20210070773-A1 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) USP19, USP16, USP18 NOTUM 2764/4885PARP1 2080/4885KDM4E 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.